Apollomics Inc. Warrant
APLMW$0.02 +0.00 (6.37%)
Company News
Apollomics, Inc. Company Operational Continuity Update
Apollomics Inc. reversed its wind-up plans after receiving $4.1 million in PIPE investments, appointed a new board and management team, and remains committed to continuing its global clinical trials for APL-101 (vebreltinib), a targeted oncology therapy.
